Agoracom Blog Home

Posts Tagged ‘CSE’

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:53 AM on Saturday, February 5th, 2022

The Roundup

A weekly summary of Novamind news and media

Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients

We are pleased to announce we have been selected by the Ketamine Research Foundation (KRF) to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness (Conscious Dying/Conscious Living Trial).

“This study is an important addition to the clinical care and research opportunities for patients within the Psychedelic Palliative Care program that we are building at Novamind,” said Dr. Paul Thielking, Chief Scientific Officer and Principal Investigator at Novamind’s Murray research site. “I’ve worked with this population for most of my career and, unfortunately, I’ve sometimes felt limited in what I can offer my patients to ease their emotional distress. The findings will contribute to the evidence for using KAP with patients who have a life-threatening illness and offer new insights into alternative treatments.”

Read the full release here.

February 3, 2022

View all press releases

February 1, 2022

Anger Issues

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the many facets of anger. They discuss the following: how conditioning affects how we process emotions like anger, the corrective emotional experience afforded by MDMA-assisted psychotherapy and much more.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

February 4, 2022

The Present and Future of Novamind, a Conversation with Citi

CEO, Yaron Conforti and Chief Medical Officer, Dr. Reid Robison recently met up with Citi to share our mission with their global investor base. 

January 31, 2022

We’re Heading into Pivotal Years for Psychedelics – Here’s Why

Dr. Reid Robison took a moment to write about his thoughts on the future of psychedelics after attending the Horizons NYC psychedelics conference.⁠

View all media

Clinical Study of Psychedelic Drugs for Cancer Patients Could Be a ‘Game Changer’

The Huntsman Cancer Institute in Salt Lake City, Utah is investigating group psilocybin therapy as a treatment for anxiety and depression in cancer patients. Dr. Paul Thielking, who serves as the study’s lead therapist, explains that even just one dose of psilocybin could entirely shift the patient’s perspective on their illness and situation. Even more remarkable? The effects of those experiences seem to last—in some case, more than four years.

Can Microdosing Psychedelics Boost Mental Health? Here’s What the Evidence Suggests

Microdosing. Does it work? Amidst increased buzz around the benefits of the practice, research continues to tackle this difficult question. This week, a new double-blind study revealed that microdosing with LSD produces “negligible changes in mood and cognition”, and there has been no research on the efficacy for people suffering from anxiety and depression. Check out National Geographic’s microdosing feature to learn more about current research, perspectives, and remaining questions.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:34 AM on Saturday, January 29th, 2022

The Roundup

A weekly summary of Novamind news and media

Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor

We are pleased to announce the closing of our previously announced private placement to an institutional investor.

Read the full release here.

January 26, 2022

View all press releases

January 25, 2022

What Causes Depression and Can Psychedelics Help?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the topic of depression and whether or not psychedelic medicine can help treat it. They discuss the following: depression and suicidal ideation, ketamine treatment for depression, the qualities to look for in a professional helper, and much more.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

January 26, 2022

Remarkable Secrets of Ketamine

Chief Medical Officer, Dr. Reid Robison sits down with The Dales Report to discuss his involvement in a number of studies involving ketamine and other drugs that target the same mechanisms. Many of the questions he’s asked along the way focus on safety considerations and optimal conditions for treatment.

Watch the full interview here.

View all media

The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of

While classic psychedelics work towards FDA approval, global drug developers are moving beyond traditional plant medicines to focus their attention on the creation of novel “precision psychedelics”, compounds with shorter trips, less side effects, and, in some cases, no hallucinogenic component. Researchers are hopeful their efforts will increase access and scalability of psychedelic treatment. “I try to think of my mom,” one COMPASS chemist explains. “If she had to have this medication, what would I want for her as an ideal compound and ideal experience?” 

Overdose Deaths Hit a Historic High in 2020. Frustrated Experts Say These Strategies Could Save Lives

100,000 overdose deaths occurred in the U.S. between April 2020 and April 2021. Despite the steady rise of overdose deaths in the U.S. over the last two decades, the latest data raises an alarm about the increased need for substance use disorder prevention and treatment. Novamind recently announced plans to develop an innovative substance use disorder program. We’re also hosting a clinical trial for ketamine-assisted psychotherapy + mindfulness for opioid use disorder. Read about it here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:28 AM on Saturday, January 22nd, 2022

The Roundup

A weekly summary of Novamind news and media

Novamind Closes Arizona Acquisition

We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.

“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”

With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.

Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”

Read the full release here.

January 18, 2022

Novamind to Participate in Citi’s Psychedelic Drug Video Call Series

We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.

Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.

“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”

To register for the call, please contact your Citi representative directly.
 

January 20, 2022

View all press releases

January 18, 2022

Can Psychedelics Change Your Personality?

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

January 14, 2022

Psychedelic Therapies Continue to Be Seen as Big Trend in Mental Health Treatment

In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.

View all media

Two Thirds of Physicians Surveyed Believe Psilocybin Therapy Has Potential Benefit for Patients With Treatment-Resistant Depression

Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.” 

MAPS Publishes Open Science Approach to Synthesizing MDMA

A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.

How Western Medicine Can Adapt to Psychedelic-Assisted Psychotherapy

Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 11:04 AM on Saturday, January 8th, 2022

A weekly summary of Novamind news and media

*The above image is a rendering and may be subject to change.

Novamind Unveils New Design Concept for Clinics

We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.

Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:

  • Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
  • Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
  • Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
  • Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
  • To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.

“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”

Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”

To see renderings of the Design Concept, click here.

January 5, 2022

View all press releases

January 4, 2022

“What is Integrative Medicine?” with Dr. Amy de la Garza

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.

December 29, 2021

Essential Qualities and Skills of the Psychedelic Therapist

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.

We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 23, 2021

Novamind Expands To Arizona

Benzinga covers our expansion into Arizona highlighting the signed definitive agreement to acquire the Foundations for Change clinics. 

View all media

Health Canada’s Special Access Program Will Now Allow Doctors To Request Patient Access To Psychedelics

This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.   

Psychedelic Healthcare in 2021

PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.

Ketamine Therapy Swiftly Reduces Depression and Suicidal Thoughts

Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

VIDEO – Valeo Pharma Immune Booster Now Available In ~300 Stores Under Loblaws Banner, Another Step Closer to 2025 Revenue Target of $160M

Posted by AGORACOM-JC at 1:40 PM on Thursday, January 6th, 2022
Valeo pharma 300x300

Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.    

This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.     

The company released stellar a Q3 with the following highlights:    

  • Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
  • Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
  • Record 9 months revenues at $10.2 million , up 94%

But wait, there’s more…

The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.

  • Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
    • Loblaws
    • Dominion,
    • Zehrs,
    • Fortinio’s,
    • Your Independent Grocer and Superstore

Steve Saviuk , CEO commented,

We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”

But wait, there’s more…

The company Closed Previously Announced Upsized $15 Million Bought Deal Private Placement And Concurrent $10 Million Private Placement with Investissement Québec.

Now sit back, relax and watch this powerful interview with Valeo Pharma.

VIDEO – Liquid Avatar Metaverse Sales Hit $1,000,000 In Preliminary Gross Revenue – Setting Up Big 2022 and Potential Token Offering

Posted by AGORACOM-JC at 6:11 PM on Wednesday, January 5th, 2022
Liquid avatar logo v1 nk

The genesis of Liquid Avatar Technologies is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified digital Identity, which also provides businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com

And if the story ended there, that would be more than enough to build a company on.

However, as the digital universe has continued to expand, there is an ever-increasing need to verify online identity as governments and enterprises around the world prepare for the shift.  For example:

  • In early 2021 Google announced a major shift away from precision-targeting of ads based on everything you do on the internet
  • The Ontario Government released its Digital Strategy, with key themes including the launch of Digital ID credentials. 

“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation,

As a result, the Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem.  Almost immediately, Liquid Avatar announced a big win here by partnering with the Ontario Convenience Stores Association (OCSA) To Provide Digital Age-Verification Solutions To Over 8,000 Stores.

Again, if the story ended there, Liquid Avatar would have the makings of a potentially massive tech company.

But with the rise of NFTs and the Metaverse, both of which strongly rely on digital identity, the Company continued to expand its core digital identity technology into these areas and registered major successes, including $1,000,000 in Preliminary Gross Revenues for its Aftermath Islands Metaverse.

In the Company’s Q4 Recap and Business Update CEO David Lucatch stated: 

“Our in-market businesses continued to perform above expectations for Q4, and we remain optimistic, while cautious, as these are still early days in the Company’s transformation to an active revenue organization. We have started to witness online acceptance of digital identity programs, which are at the core of all our solutions, and both avatar and metaverse activities are gaining traction, creating opportunities for early revenue there, as the industry embraces the future of Web 3.0. Our goal is to continue to create value for all our stakeholders.”

If you believe in the future of Web3 (blockchain, crypto, tokens, NFTs and the Metaverse) and looking for a small cap company to help you participation in it, then look no further than Liquid Avatar.  

Watch this powerful interview with CEO David Lucatch.

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:18 AM on Saturday, December 25th, 2021

The Roundup

A weekly summary of Novamind news and media

Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.

Watch on Instagram.

Novamind Signs Definitive Agreement to Acquire Arizona-based Clinics

We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.

Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.

Read the full release here.

December 23, 2021

View all press releases

December 21, 2021

Horizons: Perspectives on Psychedelics Conference Recap

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

With Health Care Workers Hurting, a Doctor Wants to See if a Psychedelic Can Help

NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.

Psychedelic-Assisted Therapy on the Rise in VA Hospitals

Lucid News covers how research partnerships exploring psychedelic-assisted psychotherapy as treatment option for veterans are gaining traction.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.

Was this email forwarded to you?
Subscribe to our weekly newsletter

BEYOND THE DECK – Blockchain Foundry SYSCOIN Market Cap Is $455 MILLION. 24 Hour Trading Volume $13M + … What Does Web 3 Know?

Posted by AGORACOM-JC at 5:20 PM on Tuesday, December 21st, 2021
Logo

We all remember the crash of “blockchain” stocks a couple of years back, which was actually a crash of blockchain pretenders who used the term to build stock promotions, as opposed to building actual blockchains.  

Like the dot-com crash of 2000, which bankrupted “dot-com” companies but gave birth to the likes of Google, Amazon, Linkedin because they built actual utility and value, the same could be expected of the blockchain crash and its’ resurgence.  

Blockchain Foundry Is A Smallcap Blockchain 2.0 Company with Real Customers, Products, Revenues and A Web3 Market Cap Of $455,000,000 For It’s Syscoin

But Blockchain Foundry is only just getting started.  The Company is building a WEB3 ecosystem on top of its powerful Sycoin blockchain which is the 2nd most secure blockchain in the world next to Bitcoin.  That isn’t a typo and Web3 coin investors believe it given the fact it has traded over $13,000,000 in volume over the last 24 hours … and close to $25,000,000 in the 24 hours before that!

What do they know that small cap investors don’t know?  What to Web3 investors know that isn’t being reflected in the $BCFN stock price? The short answer is .. A Lot … but luckily we were able to tear away CEO Dan Wasyluk from his coding marathons to explain exactly what we are missing by going through the Company’s power point presentation.

If you’re a small cap investor looking for exposure to the Web3 world of blockchain, coins, tokens, NFTs and more then this $BCFN presentation is a must-watch.

Buckle Up for one hell of a great presentation!

VIDEO – Victory Square Technologies $VST $VSQTF Eyes Web 3.0 Future via Blockchain, NFTs, Creator Economy & More

Posted by AGORACOM at 12:00 PM on Monday, December 20th, 2021
Victory Square Technologies VST

Victory Square Technologies Inc. (CSE:VST) (OTC:VSQTF) (FWB:6F6) provides investors access to a diverse portfolio of next generation technology companies in key sectors, including: Web 3.0BlockchainGaming, the Creator EconomyNFTs and the Metaverse.

“We are living in the midst of the 4th Industrial Revolution; The Tech Revolution that will undoubtedly change everything as we know it,” says VST CEO Shafin Diamond Tejani

“Web 3.0, Blockchain, Gaming, VR/AR, the Creator Economy, Digital Health and Climate Tech are all sectors that Victory Square has invested in. We offer investors the chance to invest in the most exciting tech trends all in one place with a uniquely liquid, audited and secure way to gain access to these latest innovative technologies.”

Across the next 120 days, VST’s primary goals will be to:

  • Issue The Second Tranche Of a Special Common Share Dividend of its Interest in Portfolio Company Fantasy 360 Technologies Inc. (dba Immersive Tech)
  • Assist Stardust Solar Technologies Inc., Turnium Technology Group Inc., Cassia Research Inc. (doing business as CoPilot.AI) and Shop and Shout Ltd. (doing business as Creator.co) with considering and preparing for potential public listing transactions.
  • Ramp up sales and marketing to provide Victory Square Digital Health’s full-suite of mobile digital health solutions and telemedicine platform to surgery centres, skilled nurses, home care agencies and hospice care.
  • Work with Victory Square Health to grow the Company’s roster of diagnostic tests and expand its digital health business within Brazil, the U.S. and Canada.
  • Work with Creator.co to complete the development of an add-on feature which will allow creators to launch their own digital currency powered by the blockchain.
  • Successfully incubate next batch of VST projects working on the following: Exchange Traded Protocols (Metaverse, DeFi, GameFi, DAOs), P2E (Play to Earn) Games, Decentralized Social Networks (DeSo Creator Platform).

Against this backdrop, Agoracom founder George Tsiolis sat down with the CEO to discuss the shape of the future…

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:58 AM on Saturday, December 18th, 2021

The Roundup

A weekly summary of Novamind news and media

December 14, 2021

Psychedelic Inspired Work Life Balance With Jeremiah Robison

In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Jeremiah Robison to talk about work-life balance. Jeremiah is the Founder and CEO of Shroom Beach, a psychedelic-inspired clothing company that donates 10% of its profits to fund psychedelic medicine research

Learn more, subscribe and catch up on previous episodes you may have missed at psychedelictherapyfrontiers.com

Email us questions and feedback at [email protected].

December 15, 2021

Doors Open in SLC

The announcement of our clinic launch in Salt Lake City is featured in Behavioral Health Executive and The Dales Report.
 
Both articles highlight how the new clinic will focus on treating substance use disorders and addiction-related illnesses led by incoming medical director Amy de la Garza.

View all media

Blossom Research Briefing: Eating Disorders

Blossom summarizes the exciting progress made on treating eating disorders with psychedelics. It’s a passion which our Chief Medical Officer, Dr. Reid Robison shares, working for years to bring innovative and effective treatment options to people suffering. Recently, Dr. Robison presented a keynote on the topic at the MindMed Australia International Summit on Psychedelic Therapies for Mental Illness. You can watch it here

Three Canadians With Mental Health Conditions Receive Legal Access to Psilocybin Mushrooms

Three more Canadians received legal access in a big win  that “opens it up to everyone,” but there are still issues with the system overall. “The process is still broken.” The Vancouver Sun explores how even with such positive news, there is still a lot of ground to cover in Therapsil’s fight for expanded access to psychedelic medicine. 

Across the World, COVID Anxiety and Depression Take Hold

No. We are not out of the woods. The Omicron variant is spreading quickly and with it, a slew of public health restrictions and fears reminiscent of March 2020. What can’t get lost in the shuffle again is addressing mental health. Especially for those on the frontlines of healthcare. “This sense of endlessness, accompanied by growing psychological distress leading to depression, was a recurrent theme in two dozen interviews conducted in Asia, Europe, Africa and the Americas. After two years of zigzagging policy and roller coaster emotions, terrible loss and tantalizing false dawns, closing borders and intermittently shuttered schools, people’s resilience has dwindled.” Frontline ketamine-assisted psychotherapy registration is still open for the next group of participants. Learn more here.

For further information, email us: 
[email protected]

We’re hiring!
Check out current opportunities to join our growing team.